Termination Decision Document | Mar 27, 2019 | PAPER | BOARD |
Joint Motion to Terminate | Mar 19, 2019 | PAPER | PATENT OWNER |
Joint Request to Treat Settlement Agreement as Business Confidential Information | Mar 19, 2019 | PAPER | PATENT OWNER |
Ex. 2066 EXECUTED Rituximab Settlement Agreement and License | Mar 19, 2019 | EXHIBIT | PATENT OWNER |
Granting Requests for Oral Argument | Mar 7, 2019 | PAPER | BOARD |
Petitioner's Reply in Support of Motion to Exclude Evidence Under 37 C.F.R. Section 42.64(c) | Mar 4, 2019 | PAPER | PETITIONER |
Patent Owner's Reply in Support of Motion to Exclude Evidence | Mar 4, 2019 | PAPER | PATENT OWNER |
Petitioner Pfizer's Amended Exhibit List (February 25, 2019) | Feb 25, 2019 | PAPER | PETITIONER |
Ex1063 Supplemental Evidence | Feb 25, 2019 | EXHIBIT | PETITIONER |
Ex1064 Email | Feb 25, 2019 | EXHIBIT | PETITIONER |
Patent Owner's Opposition to Petitioner's Motion to Exclude Evidence | Feb 25, 2019 | PAPER | PATENT OWNER |
Petitioner's Opposition to Patent Owner's Motion to Exclude Evidence | Feb 25, 2019 | PAPER | PETITIONER |
Patent Owner's Unopposed Motion for Pro Hac Vice Admission of David Gindler | Feb 20, 2019 | PAPER | PATENT OWNER |
Declaration of David Gindler ISO of Patent Owner's Motion for Pro Hace Vice Admission | Feb 20, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Sur-Reply | Feb 15, 2019 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Feb 15, 2019 | PAPER | PATENT OWNER |
Ex. 2063 2019-02-07 Lu Email | Feb 15, 2019 | EXHIBIT | PATENT OWNER |
Ex. 2062 Robert J. Soiffer Depo Transcript | Feb 15, 2019 | EXHIBIT | PATENT OWNER |
Ex. 2064 2019-02-15 Lu Declaration | Feb 15, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Motion to Exclude Evidence | Feb 15, 2019 | PAPER | PATENT OWNER |
Petitioner Pfizer's Motion to Exclude Evidence Under 37 C.F.R. Section 42.64(c) | Feb 15, 2019 | PAPER | PETITIONER |
Petitioner's Request for Oral Argument | Feb 11, 2019 | PAPER | PETITIONER |
Patent Owner's Request for Oral Argument | Feb 11, 2019 | PAPER | PATENT OWNER |
Patent Owner's Objections to Exhibits | Jan 31, 2019 | PAPER | PATENT OWNER |
Notice of Deposition of Robert J. Soiffer, M.D. | Jan 25, 2019 | PAPER | PATENT OWNER |
Notice of Deposition of Christopher Butler | Jan 25, 2019 | PAPER | PATENT OWNER |
EX 1059 - Butler Affidavit | Jan 24, 2019 | EXHIBIT | PETITIONER |
EX 1061 - Oleksowicz Depo. Tr. | Jan 24, 2019 | EXHIBIT | PETITIONER |
Petitioner's Reply to Patent Owner's Response | Jan 24, 2019 | PAPER | PETITIONER |
EX 1062 - Soiffer Reply Decl. | Jan 24, 2019 | EXHIBIT | PETITIONER |
Petitioner Pfizer's Amended Exhibit List (January 24, 2019) | Jan 24, 2019 | PAPER | PETITIONER |
Petitioner's Notice of Deposition of Dr. Leslie Oleksowicz | Dec 17, 2018 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notice Information Under 37 CFR Section 42.8 | Dec 17, 2018 | PAPER | PETITIONER |
Ex 2054 (Corrected) Oleksowicz Declaration with Att. A (CV) | Nov 29, 2018 | EXHIBIT | PATENT OWNER |
Petitioner's Notice of Objections to Evidence Submitted in Patent Owner's Response | Nov 20, 2018 | PAPER | PETITIONER |
Ex 2049 Maloney 1997 | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2050 Vidal 2017 | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2051 Soiffer Depo Condensed | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2053 Hall-Ellis Condensed Depo Transcript | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2056 Link 1998 | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Exhibit List | Nov 13, 2018 | PAPER | PATENT OWNER |
Ex 2052 873 IPR Soiffer Condensed Depo Transcript | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2054 Declaration of Dr. Leslie Oleksowicz in Support of Patent Owner Report | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2055 Blackwelder - Proving the Null Hypothesis | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner Response | Nov 13, 2018 | PAPER | PATENT OWNER |
Ex 2057 Solal-Celigny 1993 (Excerpts) | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2058 Habermann 2006 | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2059 White 1999 | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Ex 2060 Bird Declaration | Nov 13, 2018 | EXHIBIT | PATENT OWNER |
Notice of Joint Stipulation to Modify Due Date 4B | Nov 12, 2018 | PAPER | PATENT OWNER |
Granting Patent Owner's Request for Authorization to File a Sur-Reply
37 C.F.R. §§ 42.5(a), 42.24(c)(1) | Nov 7, 2018 | PAPER | BOARD |
Biogen's Notice of Deposition of S.D. Hall-Ellis, PH.D. | Oct 23, 2018 | PAPER | PATENT OWNER |
Notice of Deposition of Robert J. Soiffer, M.D. | Oct 8, 2018 | PAPER | PATENT OWNER |
Granting Petitioners Motion for Pro Hac Vice Recognition of
Mr. Charles B. Klein and Mr. Eimeric Reig-Plessis
37 C.F.R. sec 42.10(c) | Sep 18, 2018 | PAPER | BOARD |
Notice of Joint Stipulation to Modify Due Date 1, Due Date 2 and Due Date 4 | Sep 14, 2018 | PAPER | PATENT OWNER |
EX1060 - Declaration of Robert Soiffer, M.D. | Sep 11, 2018 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List (As of September 11, 2018) | Sep 11, 2018 | PAPER | PETITIONER |
Decision - 37 C.F.R. 42.5 | Sep 6, 2018 | PAPER | BOARD |
Order - Granting Petitioners Motion for Pro Hac Vice Recognition of
Mr. Amit H. Thakore and Mr. Leon Miniovich | Aug 31, 2018 | PAPER | BOARD |
Petitioner's Unopposed Motion to Substitute the Declaration of Dr. Ozer | Aug 22, 2018 | PAPER | PETITIONER |
Notice of Joint Stipulation to Modify Due Date 1 | Aug 9, 2018 | PAPER | PATENT OWNER |
Petitioner's Unopposed Motion For PHV Admission Of Amit H. Thakore And Leon Miniovich | Aug 1, 2018 | PAPER | PETITIONER |
Ex. 1058 Declaration Of Leon Miniovich ISO Unopposed Motion for PHV Admission | Aug 1, 2018 | EXHIBIT | PETITIONER |
Petitioner's Updated Power Of Attorney Appointing Additional Counsel | Aug 1, 2018 | PAPER | PETITIONER |
Ex. 1057 Declaration Of Amit H. Thakore ISO Unopposed Motion for PHV Admission | Aug 1, 2018 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List (As of August 1, 2018) | Aug 1, 2018 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notice | Aug 1, 2018 | PAPER | PETITIONER |
Petitioner's Objections To Exhibits | Jul 23, 2018 | PAPER | PETITIONER |
Patent Owner's Objections to Exhibits | Jul 23, 2018 | PAPER | PATENT OWNER |
Petitioner's Unopposed Motion For PHV Admission Of Charles B. Klein And Eimeric Reig-Plessis | Jul 19, 2018 | PAPER | PETITIONER |
Petitioner's Updated Exhibit List (As Of July 19, 2018) | Jul 19, 2018 | PAPER | PETITIONER |
Ex. 1055 - Declaration Of Charles B. Klein In Support Of Motion For PHV Admission | Jul 19, 2018 | EXHIBIT | PETITIONER |
Ex. 1056 - Declaration Of Eimeric Reig-Plessis In Support Of Motion For PHV Admission | Jul 19, 2018 | EXHIBIT | PETITIONER |
SCHEDULING ORDER | Jul 9, 2018 | PAPER | BOARD |
Trial Instituted Document | Jul 9, 2018 | PAPER | BOARD |
Patent Owner Preliminary Response | Apr 11, 2018 | PAPER | PATENT OWNER |
Patent Owner's Exhibit List | Apr 11, 2018 | PAPER | PATENT OWNER |
Ex 2003 Hidderman 1995 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2005 Restriction Requirement dated October 15, 2009 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2006 Response to Election Restriction as filed | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2010 Cabanillas 1992 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2013 van Oers 2006 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2016 Dana 1998 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2017 Peterson 1997 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2001 Prior Boehringer IPR Board Decision | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2002 Al-Ismail 1987 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2004 Wiernik 1996 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2009 Schein et al., 1975 Cancer | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2012 Ezdinli 1987 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2015 Arranz 1998 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2020 Davis AACR 1998 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2031 Martelli 1997 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2033 Janeway Immunobiology | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2035 Horning 1994 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2036 Chen 2015 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2040 Wang 2014 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2041 Excerpts from Physicians' Desk Reference | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2046 Boehringer 172 IPR Petition | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2018 Chisesi 1991 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2019 Rohatiner 2005 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2021 Multani-Grossbard 1998 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2023 Carlson 1997 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2025 Czuczman 1996 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2026 Grossbard 2002 (Excerpts) | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2027 Aviles 1997 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2029 Grillo-Lopez 1995 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2030 Pickup Article | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2032 Meyer 1997 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2034 Maloney 1994 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2037 Dudeja 2016 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2038 Understanding Maintenance Therapy | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2039 Grossbard 1998 | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2042 Non-Institution Decision from Celltrion (IPR2017-01093) | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2043 Celltrion 172 IPR Petition | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2044 Prior Pfizer IPR Board Decision Denying Institution | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2045 Prior Pfizer IPR Petition (IPR2017-01166) | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2047 POR Redacted from 161 IPR | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Ex 2048 Song Declaration | Apr 11, 2018 | EXHIBIT | PATENT OWNER |
Petitioner¿¿¿s Updated Mandatory Notice | Jan 31, 2018 | PAPER | PETITIONER |
Notice of Accord Filing Date | Jan 11, 2018 | PAPER | BOARD |
Patent Owner's Updated Mandatory Notice | Dec 27, 2017 | PAPER | PATENT OWNER |
Power of Attorney | Dec 21, 2017 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notice | Dec 21, 2017 | PAPER | PATENT OWNER |
Ex. 1005 - Hochster et al., "Prolonged Time to Progression (TTP) In Patients With Low Grade Lymphoma (LGL) Treated With Cyclophosphamide (C) and Fludarabine (F) [ECOG1491]," Am. Soc. of Clinical Oncology, PP, 34th Annual Meeting (May 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Petitioner's Power of Attorney (Pfizer Inc.) | Dec 14, 2017 | PAPER | PETITIONER |
Ex. 1001 - Grillo-Lopez, U.S. Patent No. 8,329,172 B2 | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1003 - Caroline McNeil, "Non-Hodgkin's Lymphoma Trials In Elderly Look Beyond CHOP," J. Nat'l Cancer Inst., 90(4):266-267 (Feb. 18, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1004 - Rituxan (rituximab) labeling (Nov. 1997) ("FDA label") | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1007 - Sriskandan et al., "Aggressive management of doxorubicin-induced
cardiomyopathy associated with 'low' doses of doxorubicin," Postgrad. Med. J., 70(828):759-761 (Oct. 1994) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Steward et al., "Maintenance Chlorambucil After CVP in the Manage-ment of Advanced Stage, Low-Grade Histologic Type Non-Hodgkin's Lymphoma,¿¿¿"Cancer, 61:441-447 (1988) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1006 - McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Anti-body Therapy for Relapsed Indolent Lymphoma: Half of Patients Re-spond to a Four-Dose Treatment Program," J. Clin. Oncol., 16:2825-2833 (Aug. 7, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1008 - Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Anti-body Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195 (Sept. 15, 1997) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1009 - Aviles et al., "Interferon Alpha 2b as Maintenance Therapy in Low Grade Malignant Lymphoma Improves Duration of Remission and Survival," Leukemia & Lymphoma, 20:495-499 (1996) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1013 - Kenneth A. Foon & Richard I. Fisher, "Lymphomas," Hematology, 5th Ed. (1995), 1076-1096 | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1014 - Michael J. Campbell & John E. Niederhuber, "B-Lymphocyte Respons-es," Clinical Oncology, Abeloff et al., Eds. (1995), 100-126 | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1020 - U.S. Provisional Patent Application No. 60/096,180 (Aug. 11, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1023 - Office Action, U.S. Patent Application No. 11/840,956 (May 11, 2010) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1026 - Hoppe et al., "The Treatment of Advanced Stage Favorable
Histology Non-Hodgkin's Lymphoma:" Blood, 58(3):592-598 (Sept. 1981) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1027 - Amendment Responsive to Examiner's Request, U.S. Patent Application No. 11/840,956 (Oct. 28, 2011) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1011 - Hiddemann et al., "Non-Hodgkin's Lymphomas-Current Status of Therapy and Future Perspectives," Eur. J. Cancer, 31A:2141-2145 (1995) ("Hiddemann II") | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1012 - Unterhalt et al., "Significant Prolongation of Disease Free Survival in Advanced Low Grade Non Hodgkin's Lymphomas (nhl) by Interfereon Alpha Maintenance," Int'l Conf. on Malignant Lymphoma (1996) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1015 - Arthur T. Skarin & David M. Dorfman, "Non-Hodgkin"s Lymphomas: Current Classification and Management," CA Cancer J. Clinicians, 47(6):351-372 (1997) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1016 - Declaration of Sylvia D. Hall-Ellis, Ph.D. | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1017 - Hiddemann et al., "New Aspects in the Treatment of Advanced Low-Grade Non-Hodgkin's Lymphomas:" Seminars in Hematology, Vol 31, No 2, Suppl 3:32-35, (1994) ("Hiddemann I") | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1018 - Bishop et al. "A Randomized Trial of High Dose Cyclophosphamide, Vincristine, and Prednisone Plus or Minus Doxorubicin (CVP versus CAVP) with Long-Term Follow-Up in Advanced Non-Hodgkin"s Lymphoma," Leukemia, 1(6):508-513(June 1987) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1019 - Specification, U.S. Patent Application No. 11/840,956 (Aug. 18, 2007) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1021 - Preliminary Amendment, U.S. Patent Application No. 11/840,956 (Oct. 31, 2007) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1022 - Amendment and Reply under 35 C.F.R. Section 1.111, U.S. Patent Applica-tion No. 11/840,956 (Aug. 25, 2010) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1024 -Notice of Allowance and Fee(s) Due, U.S. Patent Application No. 11/840,956 (June 26, 2012) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - Portlock and Rosenberg, "Combination Chemotherapy with Cyclophos-phamide, Vincristine, and Prednisone in Advanced Non-Hodgkin's Lymphomas," Cancer 37:1275-1282 (1976) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1028 - Declaration Under 37 C.F.R. Section 1.132 of Mark Benyunes, M.D. | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1029 - Hochster H., et al., "Maintenance Rituximab After Cyclophosphamide,
Vincristine, and Prednisone Prolongs Progression-Free Survival in
Advanced Indolent Lymphoma:" J. Clin. Oncol., 27(10):1607-1614 (Apr. 1, 2009) ("Hochster II") | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1030 - Patent Owner Preliminary Response, Boehringer Ingelheim Internation-al GmbH v. Biogen Inc., IPR2015-00418, Paper 11 (PTAB) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1031 - Decision Denying Institution of Inter Partes Review, Boehringer Ingelheim International GmbH v. Biogen Inc., IPR2015-00418, Paper 14 (PTAB) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1033 - Dana, B. et al., "Long-Term Follow-Up of Patients With Low-Grade
Malignant Lymphomas Treated With Doxorubicin-Based Chemotherapy or Chemoimmunotherapy," J. Clin. Oncol., 11(4):644-651 (Apr. 1993) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1034 - Solal-Celigny et al., "Doxorubicin-Containing Regimen With or without Interferon Alfa-2b for Advanced Follicular Lymphomas," J. Clin. On-col., 16(7):2332-2338 (July 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1035 - Wadler et al., "New Advances in Interferon Therapy of Cancer," The Oncologist, 2:254-267 (1997) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1037 - Habermann et al., "Rituximab-CHOP Versus CHOP Alone or With
Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma," J. Clin. Oncol., 24(19):3121-3127 (July 1, 2006) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1038 - De Nardo et al., "A Revolution in the Treatment of Non-Hodgkin's Lymphoma," Cancer Biotherapy & Radiopharmaceuticals, 13(4):213-223 (1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1039 - Physicians' Desk Reference (53rd ed. 1999) (excerpted), "Rituxan (Rituximab)" | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1043 - Charles Marwick, "Monoclonal Antibody to Treat Lymphoma," J. Am. Med. Ass'n, 278(8):616, 618 (August 27, 1997) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1044 - Sean Henahan, "Anti-CD20 Antibodies Combining Well in Lymphoma Patients," Inpharma, 1136:9 (May 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1032 - Rituxan (rituximab) labeling (rev. 2014) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1036 - Feugier, "A Review of Rituximab, the First Anti-CD20 Monoclonal An-tibody Used in the Treatment of B Non-Hodgkin's Lymphomas," Future Oncology 11(9):1327-1342 (2015) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1040 - Anderson et al., U.S. Patent No. 5,736,137, (issued Apr. 7, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1041 - "Rituxan Full Prescribing Information," Genentech Wayback Machine Website (dated January 23, 1998) ("Website label") | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1042 - Gail A. Leget and Myron S. Czuczman "Use of Rituximab, the New FDA-Approved Antibody," Current Opinion in Oncology, 10:548-551 (1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1045 - "Genentech, Inc., News," Genentech Wayback Machine Website (dated January 23, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1046 - "Genentech, Inc., Recent Press Releases," Genentech Wayback Machine Website (dated January 23, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1048 - "Genentech, Inc., Homepage," Genentech Wayback Machine Website (dated January 23, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1049 - Genentech, Inc., Search the Genentech Web Site," Genentech Wayback Machine Website (dated January 23, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1053 - Christine White and Antonio Grillo-Lopez, PCT Application Number: PCT/US99/26308, "Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody," (filed Nov. 9, 1998) (certified copy) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1047 - "Genentech, Inc., The Access Excellence Collection of Science Updates," Genentech Wayback Machine Website (dated January 23, 1998) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1050 - Genentech, Inc.'s Response to Petitioner's Additional Discovery, IPR2016-01614 (U.S. Patent 7,820,161) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1051 - Biogen, Inc.'s Response to Petitioner's Additional Discovery, IPR2016-01614 (U.S. Patent 7,820,161) | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1052 - Press Release, Genentech, Inc. "New Drug for Non-Hodgkin's Lym-phomas Available Now," (December 16, 1997) https://www.gene.com/media/press-releases/4835/1997-12-16/new-drug-for-non-hodgkins-lymphoma-avail | Dec 14, 2017 | EXHIBIT | PETITIONER |
Ex. 1054 -Rituxan (rituximab), BLA Number 103705, Drugs@FDA: FDA Ap-proved Drug Products, available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705 | Dec 14, 2017 | EXHIBIT | PETITIONER |
PETITION FOR INTER PARTES REVIEW (NHL '172) | Dec 14, 2017 | PAPER | PETITIONER |
Ex. 1002 - Declaration of Howard Ozer, M.D., Ph.D | Dec 14, 2017 | EXHIBIT | PETITIONER |